Evaluation of human thymidine kinase 1 substrates as new candidates for boron neutron capture therapy

Cancer Research

Volumn 64, Issue 17, 2004, Pages 6280-6286

  Al Madhoun, Ashraf S ^a,c   Johnsamuel, Jayaseharan ^b   Barth, Rolf F ^b   Tjarks, Werner ^b   Eriksson, Staffan ^a  

^a SWEDISH UNIVERSITY OF AGRICULTURAL SCIENCES   (Sweden)

^b OHIO STATE UNIVERSITY   (United States)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

3 (CARBORANYL)THYMIDINE; 5 (CARBORANYLMERCAPTO) 2' DEOXYURIDINE; 5' DEOXYNUCLEOTIDE; 5' MONOPHOSPHATE; DEOXYRIBONUCLEOTIDE; PYRIMIDINE NUCLEOSIDE; THYMIDINE DERIVATIVE; THYMIDINE KINASE; THYMIDINE KINASE 1 SUBSTRATE; THYMIDINE PHOSPHORYLASE; UNCLASSIFIED DRUG;

ARTICLE; BLOOD BRAIN BARRIER; BRAIN TUMOR; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; ENZYME KINETICS; ENZYME MECHANISM; HUMAN; HUMAN CELL; KINETICS; NEUTRON CAPTURE THERAPY; NUCLEOTIDE SEQUENCE; PARTITION COEFFICIENT; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TUMOR CELL CULTURE;

5'-NUCLEOTIDASE; BORON NEUTRON CAPTURE THERAPY; CELL LINE; CYTOSOL; HUMANS; KINETICS; NUCLEOTIDASES; PHOSPHORYLATION; SUBSTRATE SPECIFICITY; THYMIDINE; THYMIDINE KINASE;

EID: 4344567355     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-0197     Document Type: Article

References (37)

1. Capala J, Stensam BH, Sköld K, at al. Boron neutron capture therapy for glioblastoma multiforme: Clinical studies in Sweden. J Neuro-Oncol 2003;62:123-34.
2. Nakagawa Y, Pooh K, Kobayashi T, et al. Clinical review of the Japanese experience with boron neutron capture therapy trails and a proposed strategy using epithelial neutron beams. J Neuro-Oncol 2003;62:101-9.
3. Busse PM, Harling OK, Palmer MR, et al. A critical examination of the results from the Harvard-MIT NCT program phase 1 clinical trial of neutron capture therapy for intracranial disease. J Neuro-Oncol 2003;62:111-21.
4. Soloway AH, Tjarks W, Barnum BA, et al. The chemistry of neutron capture therapy. Chem Rev 1998;98:1515-62.
5. Barth RF, Soloway AH, Goodman JH, et al. Boron neutron capture therapy of brain tumors: an emerging therapeutic modality. Neurosurgery 1999;44:433-51.
6. Tjarks W. The use of boron clusters in the rational design of boronated nucleosides for neutron capture therapy of cancer. J Organomet Chem 2000;614-615: 37-47.
7. Eriksson S, Munch-Petersen B, Johansson K, Eklund H. Structure and function of cellular deoxyribonucleoside kinases. Cell Mol Life Sci 2002;59:1327-46.
8. Lunato AJ, Wang J, Woollard JE, et al. Synthesis of 5- (carboranylalkylmercapto)-2′-deoxyuridines and 3-(carboranylalkyl) thymidines and their evaluation as substrates for human thymidine kinases 1 and 2. J Med Chem 1999;42:3373-89.
9. Al-Madhoun AS, Johnsamuel J, Yan J, et al. Synthesis of a small library of 3-(carboranylalkyl) thymidines and their biological evaluation as substrates for human thymidine kinases 1 and 2. J Med Chem 2002;45:4018-28.
10. Tjarks W, Anisuzzaman AK, Liu L, et al. Synthesis and in vitro evaluation of boronated uridine and glucose derivatives for boron neutron capture therapy. J Med Chem 1992;35:1628-33.
11. Al-Madhoun AS, Tjarks W, Eriksson S. The role of thymidine kinases in the activation of pyrimidine nucleoside analogues. Mini Rev Med Chem 2004;4:341-50.
12. Balzarini J, Sienaert R, Liekens S, et al. Lack of susceptibility of bicyclic nucleoside analogs, highly potent inhibitors of varicella-zoster virus, to the catabolic action of thymidine phosphorylase and dihydropyrimidine dehydrogenase. Mol Pharmacol 2002;61:1140-5.
13. Rampazzo C, Gazziola C, Ferraro P, et al. Human high-Km 5′-nucleotidase effects of overexpression of the cloned cDNA in cultured human cells. Eur J Biochem 1999; 261:689-97.
14. Kit S, Dubbs DR, Piekarski LJ, Hsu TC. Deletion of thymidine kinase activity from L cells resistant to bromodeoxyuridine. Exp Cell Res 1963;31:297-312.
15. Tornevik Y, Ullman B, Balzarini J, Wahren B, Eriksson S. Cytotoxicity of 3′-azido-3′-deoxythymidine correlates with 3′-azidothymidihe- 5′-monophosphate (AZTMP) levels, whereas anti-human immunodeficiency virus (HIV) activity correlates with 3′-azidothymidine-5′-triphosphate (AZTTP) levels in cultured CEM T-lymphoblastoid cells. Biochem Pharmacol 1995;49:829-37.
16. Mori S, Heldin C-H, Claesson-Welsh L. Ligand-induced polyubiquitination of the platelet-derived growth factor beta-receptor. J Biol Chem 1992;267:6429-34.
17. Kneckt W, Munch-Petersen B, Piskur J. Identification of residues involved in the specificity and regulation of the highly efficient multisubstrate deoxyribonucleoside kinase from Drosophila melanogaster. J Med Biol 2000;301:827-37.
18. Balzarini J, Degreve B, Esteban-Gamboa A, et al. Kinetic analysis of novel multisubstrate analogue inhibitors of thymidine phosphorylase. FEBS Lett 2000;483: 181-5.
19. Teijeiro SA, Moroni GN, Motura MI, Brinon MC. Lipophilic character of pyrimidinic nucleoside derivatives: correlation between shake flask, chromatographic (RP-TLC and RP-HPLC) and theoretical methods. J Li Qchrom Rel Technol 2000;23:855-72.
20. Keisari Y. A Colorimetric microtiter assay for the quantitation of cytokine activity on adherent cells in tissue culture. J Immunol Methods 1992;146:155-61.
21. Lotfi K, Mansson E, Spasokoukotskaja T, et al. Biochemical pharmacology and resistance to 2-chloro-2′-arabino-fluoro-2′-deoxyadenosine, a novel analogue of cladribine in human leukemic cells. Clin Cancer Res 1999;5:2438-44.
22. Adams DM, Ji W, Barth RF, Tjarks W. Comparative in vitro evaluation of dequalinium B, a new boron carrier for neutron capture therapy (NCT). Anticancer Res 2000;20:3395-402.
23. Lowe CR, Harvey MJ, Craven DB, Dean PDG. Some parameters relevant to affinity chromatography on immobilized nucleotides. Biochem J 1973; 133:499-506.
24. Adams DR, Perez C, Maillard M, et al. Preparation and anti-HIV activity of N-3-substituted thymidine nucleoside analogs. J Med Chem 1997;40:1550-8.
25. Asano S, Yokoyama Y, Kohda K. Growth inhibition of cultured human leukemia cells by 3-aminothymidine and its analogue. Anticancer Res 17:823-6, 1997.
26. Eriksson S, Wang J. Substrate specificities of mitochondrial thymidine kinase and cytosolic deoxycytidine kinase against 5-aryl substituted pyrimidine-2′-deoxyribose analogues. Nucleosides Nucleotides 14:507-10, 1995.
27. Johansson NJ, Eriksson S. Structure-activity relationships for the phosphorylation of nucleoside analogs to monophosphates by nucleoside kinases. Acta Biochim Pol 1996;43:143-60.
28. Wang J, Su C, Neuhard J, Eriksson S. Expression of human mitochondrial thymidine kinase in E. Coli: correlation between the enzymatic activity of the pyrimidine nucleoside analogues and their inhibitory effect on bacterial growth. Biochem Pharmacol 2000;59:1583-8.
29. Yan J, Naeslund C, Al-Madhoun AS, et al. Synthesis and biological evaluation of 3′-carboranyl thymidine analogues. Bioorg Med Chem Lett 2002;12:2209-12.
30. Tjarks W, Wang J, Chandra S, et al. Synthesis and biological evaluation of boronated nucleosides for boron neutron capture therapy (BNCT) of cancer. Nucleosides Nucleotides Nucleic Acids 2001;20:695-8.
31. Yun M, Park C, Kin J, Rock CO, Jackowski S, Park H. Structural basis for the feedback regulation of Escherichia coli pantothenate kinase by coenzyme A. J Biol Chem 2000;275:28093-9.
32. Knecht W, Petersen GE, Munch-Petersen B, Piskur J. Deoxyribonucleoside kinases belonging to the thymidine kinase 2 (TK2)-like group vary significantly in substrate specificity, kinetics and feed-back regulation. J Mol Biol 2002;315: 529-40.
33. Rampazzo C, Johansson M, Gallinaro L, et al. Mammalian 5′(3′)-deoxyribonucleotidase, cDNA cloning, and overexpression of the enzyme in Escherichia coli and mammalian cells. J Biol Chem 2000;275:5409-15.
34. Chen MS, Suttmann RT, Wu JC, Prisbe EJ. Metabolism of 4′- azidothymidine, a compound with potent and selective activity against the human immunodeficiency virus. J Biol Chem 1992;267:257-60.
35. Atkinson F, Cole S, Green C, Van De Weterbeemd H. Lipophilicity and other parameters affecting brain penetration. Curr Med Chem 2002;2:229-40.
36. Hansch C, Bjorkroth JP, Leo A. Hydrophobicity and central nervous system agents: on the principle of minimal hydrophobicity in drug design. J Pharm Sci 1987;76: 663-87.
37. Barth RF, Yang W, Al-Madhoun AS, et al. Boron containing nucleosides as potential delivery agents for neutron capture therapy of brain tumors. Cancer Res. 2004;64: 6287-95.